EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC 4.0

Exposure to biologic therapy before and during pregnancy in patients with psoriasis: Systematic review and meta‐analysis

V Sánchez-García iD, R Hernández-Quiles iD, E de-Miguel-Balsa iD, Á Giménez-Richarte iD, J M Ramos-Rincón iD, I Belinchón-Romero iD

Journal of the European Academy of Dermatology and Venereology · 2023

DOI: 10.1111/jdv.19238 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2023. Verfasst von V Sánchez-García und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain. Hauptthemen laut MEDLINE: Abortion, Spontaneous, Psoriasis, Biological Products. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biologicals have transformed the management of severe disease phenotypes in psoriasis and are often prescribed in women of childbearing age. However, information on safety of biologicals in pregnancy are lacking. We conducted a systematic review and meta‐analysis aimed to describe the characteristics and pregnancy outcomes in women with psoriasis exposed to biologics within 3 months before or during pregnancy, and to estimate the pooled prevalence of spontaneous, elective and total abortions, and congenital malformations in their newborns. Bibliographic searches were performed in the PubMed, Embase, Scopus and Web of Science databases up to 14 April 2022. No restrictions on sample size or publication date were applied. Review performance complied with PRISMA guidelines, and two reviewers assessed randomized controlled trials and nonrandomized studies reporting pregnancy outcomes in women exposed to biologics indicated for psoriasis during the pre‐gestational and/or gestational period. Studies focusing on rheumatologic or gastroenterological immune‐mediated inflammatory diseases were excluded. Regardless of data heterogeneity, a random‐effects model was used to pool prevalence estimates. We included 51 observational studies, involving 739 pregnancies exposed to approved biologics for psoriasis. Administration was mostly (70.4%) limited to the first trimester, and the most common drug was ustekinumab (36.0%). The estimated prevalence of miscarriage was 15.3% (95% confidence interval [CI] 12.7–18.0) and elective abortions, 10.8% (95% CI 7.7–14.3). Congenital malformations occurred in about 3.0% (95% CI 1.6–4.8) of live births exposed to biologics during pregnancy. Altogether, exposure to biologics for psoriasis during pregnancy and/or conception does not seem to be associated with an increased risk of miscarriage/abortion or congenital malformations, showing similar rates to the general population. These results suggest that biologic drugs are safe and pose an acceptable risk to the foetuses/neonates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Abortion, SpontaneousPsoriasisBiological ProductsInfant, NewbornPregnancyHumansFemaleUstekinumabPregnancy OutcomeBiological Therapy

Substanzen

UstekinumabBiological Products

Autor:innen und Institutionen

  • Dermatology Department, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.
  • Department of Clinical Medicine, Miguel Hernández University, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.
  • Valencian Community Blood Transfusion Center, Valencia, Spain.

ORCID-Profile: V Sánchez-García, R Hernández-Quiles, E de-Miguel-Balsa, Á Giménez-Richarte, J M Ramos-Rincón, I Belinchón-Romero

Zitieren

APA

Sánchez-García, V., Hernández-Quiles, R., de-Miguel-Balsa, E., Giménez-Richarte, Á., Ramos-Rincón, J. M., & Belinchón-Romero, I. (2023). Exposure to biologic therapy before and during pregnancy in patients with psoriasis: Systematic review and meta‐analysis. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19238

Vancouver

Sánchez-García V, Hernández-Quiles R, de-Miguel-Balsa E, Giménez-Richarte Á, Ramos-Rincón JM, Belinchón-Romero I. Exposure to biologic therapy before and during pregnancy in patients with psoriasis: Systematic review and meta‐analysis. Journal of the European Academy of Dermatology and Venereology. 2023. doi:10.1111/jdv.19238

BibTeX
@article{SnchezGarca2023,
  author = {Sánchez-García, V and Hernández-Quiles, R and de-Miguel-Balsa, E and Giménez-Richarte, Á and Ramos-Rincón, J M and Belinchón-Romero, I},
  title = {Exposure to biologic therapy before and during pregnancy in patients with psoriasis: Systematic review and meta‐analysis},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2023},
  doi = {10.1111/jdv.19238}
}
Kostenlos starten →